Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

Launched by DENISE FABIAN · Jul 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of molecular biomarkers in women who have been diagnosed with uterine cervix cancer. Specifically, it aims to understand how certain biological markers in the blood can help track the disease and the effectiveness of treatments. Women participating in the trial will receive standard treatments, which include chemotherapy combined with radiation therapy, followed by a type of radiation therapy called brachytherapy. Researchers will collect blood samples to look for specific substances that may indicate the presence of cancer or how well the treatment is working.

To be eligible for this trial, women should be between the ages of 65 and 74 and must have a confirmed diagnosis of a specific stage of cervical cancer that cannot be treated with surgery alone. This study is currently recruiting participants, but women with other active cancers or those who have had certain previous cancers or radiation treatments may not qualify. Participants can expect to receive the standard care for their condition while contributing to important research that could improve future treatments for cervical cancer.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • - Untreated pathologically or cytologically-confirmed diagnosis of stage IB3 (\> 4cm), II, III, or IVA (FIGO 2018) squamous, adenosquamous, or adenocarcinoma of the uterine cervix not amenable to curative surgery alone.
• Exclusion Criteria:
• • Presence of another concurrent active invasive malignancy
• • Prior invasive malignancy diagnosed within the last three years except for \[1\] non-melanoma skin cancer or \[2\] prior in situ carcinoma of the cervix
• • prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician.